^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | denifanstat (TVB-2640) (FASN inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
Published date:
03/30/2021
Excerpt:
Overall, 136 patients received TVB-2640...In combination with paclitaxel, the PR rate was 11% and the DCR was 70%. Responses were seen across multiple tumor types, including in patients with KRASMUT NSCLC, ovarian, and breast cancer.
Secondary therapy:
paclitaxel
DOI:
10.1016/j.eclinm.2021.100797
Trial ID: